Scholars Central

Conference abstractPublished 27 Nov 2017

The etiology of early mortality in pediatric acute leukemia

Authors: Asghar Bazrafshan

Shiraz University of Medical Sciences, Iran

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Early death means death occurs before remission or within 30 days of starting induction chemotherapy. The rate of early death in ALL is about 1-5%. The most common cause of early death was infection, which was mainly bacterial. The second leading cause was bleeding, frequently stated brain hemorrhage and septic shock was the third most common cause. The other causes were tumor lysis syndrome and hyperleukocytosis, drug related encephalopathy, acute cardiomyopathy and thrombotic events. The differences of early mortality rate in different studies seem to be due to following causes: Age of patients, sex, type of treatment, preexisting disorder like Down syndrome and high white blood cell count. Children with acute lymphoblastic leukemia needs more advanced supportive care mainly focused on strategies to prevent infection and bleeding, which was the most common causes of early deaths. Advance supportive cares to prevent infection include starting IVIg for infant and prophylaxis against Pneumocystis jiroveci with trimethoprim/sulfamethoxazole in neutropenic patients during induction and bleeding by transfusion support as well as modification in anthracycline dose. In addition, it is necessary to individualize the patient for using the type of corticosteroid during induction phase with performing further studies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Asghar Bazrafshan”